deltatrials
Unknown PHASE2 NCT01193855

Dutasteride in Treating Patients With Prostate Cancer

Single Site, Phase II, Double Blind, Randomized, Placebo Controlled Study of the Effect of Dutasteride (Avodart) 0.5mg on the Volume and Characteristics of Prostate Cancer, as Assessed by Multifunctional Magnetic Resonance Imaging (MRI) With Lower Risk Prostate Cancer Suitable for Active Surveillance. (MAPPED TRIAL)

Sponsor: University College London Hospitals

Conditions Prostate Cancer
Interventions active surveillance diffusion-weighted magnetic resonance imaging dutasteride functional magnetic resonance imaging gadolinium-chelate prostate biopsy ultrasound imaging
Updated 5 times since 2017 Last updated: Aug 23, 2013 Started: Jun 30, 2010 Primary completion: Jan 31, 2012

Listed as NCT01193855, this PHASE2 trial focuses on Prostate Cancer and remains ongoing. Sponsored by University College London Hospitals, it has been updated 5 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University College London Hospitals
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • London, United Kingdom